Yu Meijia, Zhang Qin, Zhao Xia
Department of Gynecology and Obstetrics, Development and Related Disease of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, China.
Department of Obstetrics and Gynecology, The First Hospital of Affiliated to Army Medical University, Chongqing, China.
Front Oncol. 2022 Aug 19;12:973077. doi: 10.3389/fonc.2022.973077. eCollection 2022.
Although the association between MDM2 rs2279744 and TP53 rs1042522 polymorphisms and cervical cancer has been reported, the results of its correlation were contradictory. Thus, we conducted a meta-analysis to precisely verify the relationships between MDM2 rs2279744 and TP53 rs1042522 polymorphisms and cervical cancer.
We thoroughly searched the PubMed, Web of Science, Embase, and Scopus databases for all potential articles from inception to June 2022 and used R Version 4.1.2 and STATA software 12.0 for the meta-analysis. The odds ratios (ORs), 95% confidence intervals (CIs) and 95% prediction intervals (PIs) were calculated to evaluate the associations. Subgroup analyses stratified by ethnicity, source of control, quality score and adjustment were further conducted to assess the relationship between MDM2 rs2279744 and TP53 rs1042522 polymorphisms and cervical cancer.
A total of 30 case-control studies involving 5025 cases and 6680 controls were included. All the included studies were population-based or hospital-based studies. The overall analysis showed that MDM2 rs2279744 polymorphism was closely related to an increased risk of cervical cancer in the recessive model (GG vs GT + TT: OR = 1.602, 95% CI: 1.077-2.383, P = 0.020) and homozygote model (GG vs TT: OR = 1.469, 95% CI: 1.031-2.095, P = 0.033, 95% PI: 0.516-4.184). A significant correlation between TP53 rs1042522 polymorphism and cervical cancer was observed in two models (CC + CG vs GG: OR = 1.759, 95% CI: 1.192-2.596, P = 0.004, 95% PI: 0.474-6.533; GG vs CC: OR = 2.442, 95% CI: 1.433-4.162, P = 0.001, 95% PI: 0.456-13.071).
This meta-analysis revealed that MDM2 SNP309T>G and TP53 rs1042522 C>G polymorphisms were associated with the increased risk of cervical cancer.
尽管已有报道称MDM2基因rs2279744多态性和TP53基因rs1042522多态性与宫颈癌之间存在关联，但其相关性结果相互矛盾。因此，我们进行了一项荟萃分析，以精确验证MDM2基因rs2279744多态性和TP53基因rs1042522多态性与宫颈癌之间的关系。
我们全面检索了PubMed、Web of Science、Embase和Scopus数据库，查找从数据库建立至2022年6月的所有相关文章，并使用R 4.1.2版本和STATA 12.0软件进行荟萃分析。计算比值比（OR）、95%置信区间（CI）和95%预测区间（PI）以评估关联。进一步进行按种族、对照来源、质量评分和调整分层的亚组分析，以评估MDM2基因rs2279744多态性和TP53基因rs1042522多态性与宫颈癌之间的关系。
共纳入30项病例对照研究，涉及5025例病例和6680例对照。所有纳入研究均为基于人群或基于医院的研究。总体分析表明，在隐性模型（GG与GT + TT比较：OR = 1.602，95% CI：1.077 - 2.383，P = 0.020）和纯合子模型（GG与TT比较：OR = 1.469，95% CI：1.031 - 2.095，P = 0.033，95% PI：0.516 - 4.184）中，MDM2基因rs2279744多态性与宫颈癌风险增加密切相关。在两个模型中观察到TP53基因rs1042522多态性与宫颈癌之间存在显著相关性（CC + CG与GG比较：OR = 1.759，95% CI：1.192 - 2.596，P = 0.004，95% PI：0.474 - 6.533；GG与CC比较：OR = 2.442，95% CI：1.433 - 4.162，P = 0.001，95% PI：0.456 - 13.071）。
这项荟萃分析表明，MDM2基因SNP309T>G和TP53基因rs1042522 C>G多态性与宫颈癌风险增加相关。
